Virax Biolabs Group Limited (VRAX)
| Market Cap | 22.70M |
| Revenue (ttm) | 8,561 |
| Net Income (ttm) | -5.46M |
| Shares Out | 15.55M |
| EPS (ttm) | -5.10 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 175,180 |
| Open | 1.61 |
| Previous Close | 1.61 |
| Day's Range | 1.43 - 1.62 |
| 52-Week Range | 1.28 - 16.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 25, 2024 |
About VRAX
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as ... [Read more]
Financial Performance
Financial StatementsNews
Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients
LONDON , Dec. 21, 2023 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagn...
Virax Biolabs' CEO James Foster Issues Letter to Shareholders
LONDON , Dec. 18, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), today announced that Mr. James Foster, Chief Executive Officer of Virax, has issued a lett...
Virax Biolabs Group Limited Announces 1-for-10 Share Consolidation
LONDON , Dec. 14, 2023 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative diagnostics company focused on the detection of immune responses and diagnos...
Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar
LONDON , Sept. 12, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune responses and diagno...
Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum
LONDON , Sept. 1, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune responses and diagnos...
Nasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 Bid
LONDON , Aug. 3, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune responses and diagnosi...
Virax Biolabs Group Continues Growth and Expansion with the Addition of Research and Laboratory Facilities
LONDON and DUBAI, UAE, July 18, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune respons...
Virax Biolabs Group Announces Establishment of Regional Headquarters at Dubai Science Park
LONDON and DUBAI, UAE, May 4, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune responses...
Virax Biolabs Group Limited Has Entered into an Agreement for the Distribution of Marburg Virus PCR Testing Kits
LONDON , April 19, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotech company focused on the detection of immune responses to and diagnos...
Virax Biolabs Group Limited Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
LONDON , March 10, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis o...
Virax Biolabs Group Limited Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
LONDON , March 8, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of...
Virax Biolabs Group Limited Introduces Avian Influenza A Virus Real-Time PCR Test Kit
LONDON , March 7, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of v...
Cosmos Health Announces Initial Purchase Order with Virax Biolabs for the Distribution of COVID-19 and Influenza A+B Antigen Combo Rapid Tests
CHICAGO, IL / ACCESSWIRE / February 7, 2023 / Cosmos Health Inc. ("the Company") (NASDAQ:COSM) , a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, ...
Virax Biolabs Group Limited Announces Purchase Order to Launch COVID-19 and Influenza A+B Antigen Combo Rapid Tests with Cosmos Health (NASDAQ:COSM)
LONDON , Feb. 7, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of vi...
Virax Biolabs to Present at the 2023 BIO CEO & Investor Conference
LONDON , Feb. 6, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of vi...
Virax Biolabs Introduces Human Papillomavirus ("HPV") Test Kit
Kit Available Now for Distribution LONDON , Jan. 4, 2023 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detecti...
COVID-19 Rapid Antigen Test Distributed By Virax Biolabs Receives Emergency Use Authorization in the United States
Kits available Now for Distribution LONDON , Dec. 6, 2022 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prev...
Virax Biolabs Appoints Richard Pallin as the Vice President of In Vitro Diagnostic Sales
LONDON , Nov. 15, 2022 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral disease...
Virax Biolabs Group Limited Announces Closing of $3.8 Million Private Placement
LONDON , Nov. 8, 2022 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of ...
Virax Biolabs Group Limited Announces $3.8 Million Private Placement
LONDON , Nov. 4, 2022 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of ...
Virax Biolabs Introduces RSV-Influenza-COVID Triple Virus Antigen Rapid Test Kit
Kits available in November for Distribution LONDON , Nov. 3, 2022 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention...
Virax Biolabs Group Limited Announces Initiation of its Virax Immune COVID-19 Analytical Performance Study
LONDON , Oct. 26, 2022 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagn...
Virax Biolabs Group Limited Announces Distribution Agreement to Market Monkeypox Virus Real-Time PCR Detection Kit with Cosmos Holdings Inc.
Exclusive distribution agreement signed with Cosmos Holdings Inc. (Nasdaq: COSM), providing for exclusive distribution rights in Greece and Cyrus with the opportunity for Cosmos to distribute across E...
Virax BioLabs Presents at H.C. Wainwright's 24th Annual Global Investment Conference
LONDON , Sept. 12, 2022 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (NASDAQ: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseas...
Virax Biolabs Group Limited to Present at H.C. Wainwright's 24th Annual Global Investment Conference in New York, NY
LONDON , Sept. 6, 2022 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of...